Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials
P. Andrew(Family Health International 360), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Michal Juraska(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Robert De La Grecca(Infectious Disease Research Institute), J.R. Mascola, Srilatha Edupuganti(Emory University), Stephen R. Walsh(Beth Israel Deaconess Medical Center), M. Cohen(University of North Carolina at Chapel Hill), Catherine Orrell(South African Medical Research Council), Simbarashe Takuva(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Javier Valencia(Asociación Civil Impacta Salud y Educación), Avneet Randhawa, Alice Sehurutshi(Botswana Harvard AIDS Institute Partnership), Christian Karg, D. Burns, Erika Rudnicki(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Lawrence Corey(Fred Hutch Cancer Center), Larissa M. Villela(Fundação Oswaldo Cruz), Shelly Karuna(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Kathryn Mngadi(Aurum Institute), J. Ledgerwood, G. Lorenzo(IMEC), L. Naidoo, M.R. Gaudinski, M. Anderson, Nyaradzo Mgodi(University of Zimbabwe)
Cited by 0
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection
|New England Journal of Medicine|1990|1.3k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
|New England Journal of Medicine|2016|768